Literature DB >> 19935030

Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050.

Jennifer M Wu1, Andrew F Hundley, Rebekah G Fulton, Evan R Myers.   

Abstract

OBJECTIVES: To estimate the number of women who will have symptomatic pelvic floor disorders in the United States from 2010 to 2050.
METHODS: We used population projections from the U.S. Census Bureau from 2010 to 2050 and published age-specific prevalence estimates for bothersome, symptomatic pelvic floor disorders (urinary incontinence [UI], fecal incontinence, and pelvic organ prolapse [POP]) from the 2005 National Health and Nutrition Examination Survey. We abstracted data regarding the number of women aged 20 years or older in 20-year age groups. We assumed that the age-specific prevalences for these disorders and the population distribution of risk factors remained unchanged thru 2050. We also conducted sensitivity analyses that varied both the prevalence estimates and the population projections.
RESULTS: The number of American women with at least one pelvic floor disorder will increase from 28.1 million in 2010 to 43.8 million in 2050. During this time period, the number of women with UI will increase 55% from 18.3 million to 28.4 million. For fecal incontinence, the number of affected women will increase 59% from 10.6 to 16.8 million, and the number of women with POP will increase 46% from 3.3 to 4.9 million. The highest projections for 2050 estimate that 58.2 million women will have at least one pelvic floor disorder, with 41.3 million with UI, 25.3 million with fecal incontinence, and 9.2 million with POP.
CONCLUSION: The prevalence of pelvic floor disorders will increase substantially given the changing demographics in the United States. This increase has important implications for public health and the field of gynecology. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Year:  2009        PMID: 19935030     DOI: 10.1097/AOG.0b013e3181c2ce96

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  154 in total

1.  Differences in recurrent prolapse at 1 year after total vs supracervical hysterectomy and robotic sacrocolpopexy.

Authors:  Erinn M Myers; Lauren Siff; Blake Osmundsen; Elizabeth Geller; Catherine A Matthews
Journal:  Int Urogynecol J       Date:  2014-11-01       Impact factor: 2.894

Review 2.  Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines.

Authors:  David D Rahn; Renée M Ward; Tatiana V Sanses; Cassandra Carberry; Mamta M Mamik; Kate V Meriwether; Cedric K Olivera; Husam Abed; Ethan M Balk; Miles Murphy
Journal:  Int Urogynecol J       Date:  2014-11-13       Impact factor: 2.894

3.  Epidemiologic Trends and Diagnostic Evaluation of Fecal Incontinence.

Authors:  Amol Sharma; Satish S C Rao
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-06

4.  Anterior and posterior compartment 3D endovaginal ultrasound anatomy based on direct histologic comparison.

Authors:  S Abbas Shobeiri; Dena White; Lieschen H Quiroz; Mikio A Nihira
Journal:  Int Urogynecol J       Date:  2012-03-09       Impact factor: 2.894

5.  Factors associated with exposure of transvaginally placed polypropylene mesh for pelvic organ prolapse.

Authors:  Karen P Gold; Renee M Ward; Carl W Zimmerman; Daniel H Biller; Shawn McGuinn; James C Slaughter; Roger R Dmochowski
Journal:  Int Urogynecol J       Date:  2012-03-24       Impact factor: 2.894

6.  Female urology-future and present.

Authors:  Cristian P Ilie; Michael B Chancellor
Journal:  Rev Urol       Date:  2010

7.  Quantification of vaginal support: are continuous summary scores better than POPQ stage?

Authors:  Linda Brubaker; Matthew D Barber; Ingrid Nygaard; Charlie W Nager; Edward Varner; Joseph Schaffer; Anthony Visco; Susan Meikle; Cathie Spino
Journal:  Am J Obstet Gynecol       Date:  2010-08-21       Impact factor: 8.661

8.  Short-term outcomes of vaginal mesh placement among female Medicare beneficiaries.

Authors:  Jennifer T Anger; Aqsa A Khan; Karyn S Eilber; Erin Chong; Stephanie Histed; Ning Wu; Chris L Pashos; J Quentin Clemens
Journal:  Urology       Date:  2014-04       Impact factor: 2.649

9.  Labhardt's colpoperineocleisis: subjective results of an alternative treatment for genital prolapse in patients who are not sexually active--2-year follow-up.

Authors:  Javier Pizarro-Berdichevsky; Gonzalo Galleguillos; Rodrigo Cuevas; Bernardita Blümel; Alejandro Pattillo; Silvana González; Alejandro Majerson; Oslando Padilla; Mauricio Cuello; Juan Andrés Ortiz; Howard B Goldman
Journal:  Int Urogynecol J       Date:  2013-09-19       Impact factor: 2.894

10.  Conceptual framework for patient-important treatment outcomes for pelvic organ prolapse.

Authors:  Vivian W Sung; Rebecca G Rogers; Matthew D Barber; Melissa A Clark
Journal:  Neurourol Urodyn       Date:  2013-03-13       Impact factor: 2.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.